A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs HTD 1801 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors HighTide Biopharma
- 26 Nov 2018 Status changed from not yet recruiting to recruiting.
- 07 Nov 2018 Planned initiation date changed from 31 Oct 2018 to 30 Nov 2018.
- 10 Sep 2018 New trial record